Veeva unveils Study Builder Agent to accelerate clinical study setup

Veeva Systems announced a new AI-powered tool, the Veeva Study Builder Agent, that configures electronic data capture (EDC) forms, data quality checks, and related listings directly from a study protocol. The aim is to speed up the setup of clinical studies while keeping standards consistent and audit-ready.

What changed with Study Builder Agent

The Study Builder Agent is described as an AI solution that automatically creates EDC forms, visits, edit checks, and DQS (Data Quality System) rules from a trial protocol. It reuses an organization’s existing standards and follows the CDISC Unified Study Definitions Model (USDM) to ensure consistency. It also automates testing, including generating test data, and focuses on reducing deviations from established standards so results are audit-ready by design.

Who is affected by this tool

Biopharmaceutical companies and research organizations that run clinical trials could benefit by faster study builds and more deterministic configurations. Users include data managers, clinical operations teams, and quality teams responsible for ensuring protocols align with company standards and regulatory expectations.

Practical next steps for organizations

If your organization conducts clinical studies, assess whether your current EDC and DQS configurations rely on evolving standards and CDISC models. Consider pilot testing the Study Builder Agent to gauge how much time is saved in configuring forms, checks, and listings, and to verify that the automatic testing and data generation fit your validation needs. Plan for change management to integrate the tool with existing IT and governance processes, and ensure audit trails remain intact as required by regulatory bodies.

Limits and open questions

Key details from the announcement focus on capabilities and intended benefits, but practical limits—such as compatibility with specific therapeutic areas, custom deviations from standards, or regulatory acceptability in different regions—aren’t specified. Organizations should seek direct guidance from Veeva on supported protocol formats, integration requirements, and validation expectations before broad deployment.

Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.